Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsWhen multiple antibodies have similar affinities for a target, determining whether they bind to the same or different epitopes on the target molecule becomes an inevitable step towards evaluating their individual functional potential. Using our Octet system, Creative biolabs can conduct the epitope binning analysis using samples either purified or directly from hybridoma supernatant or similar matrices.
Octet® system performs sample analysis in 96- and 384-well format, processing up to 16 samples in parallel and requiring only 80 μL-120 μL/well samples in 384 well plates. Antibodies can be assayed in crude mixtures (cell lysates or hybridoma supernatants) or in DMSO (up to 10%) and glycerol, thus drastically reduce the need for sample preparation. The analytical capability of the platform ensures significantly easier, faster and better characterization of antibodies, helping researchers further characterize the specificity of the clones and their ability to block target activity, which can have far-reaching effects on the candidate’s efficacy and pharmacokinetics.
Fig. 1 Octet data for an array of mAbs binding to Ag that was immobilized in different ways (as indicated in the plot titles). (Abdiche et al. 2012)
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
